Further research is needed to investigate whether vWF plasma concentrations could be used to identify patients with a low CHA2DS2-VASc score who are at moderate risk of stroke or other cardiovascular events and might benefit from oral anticoagulant (OAC) therapy [53]. The gene discussed is VWF; the disease is Stroke.